SimranSekhonMD

Gastrointestinal Cancer, Hematologic Oncology, Hospice & Palliative

Attending physician

Dr. Sekhon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
2823 Fresno St
Fresno, CA 93721
Phone+1 559-443-2682

Fax+1 559-443-2681

University of TennesseeFellowship, Hematology and Medical Oncology, 2022 - 2025
Stanford Health Care-Sponsored Stanford UniversityFellowship, Hospice and Palliative Medicine, 2019 - 2020
San Joaquin General HospitalResidency, Internal Medicine, 2011 - 2014
Manipal College of Medical ScienceClass of 2008

PubMed

13 citations
Isolated pulmonary valve endocarditis: truth or myth?
Siamak M. Seraj, Evanpaul Gill, Simranjit Sekhon
Journal of Community Hospital Internal Medicine Perspectives. 2017-10-18
Culture Eats Strategy for Breakfast: Reflections on Wang (DOI: 10.1089/jpm.2019.0251) Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients in ...
Henry Zeng, Simran Sekhon, Vyjeyanthi S. Periyakoil
Journal of Palliative Medicine. 2020-01-01
Why do patients revoke hospice in the emergency department
Henry Zeng, Bhoomika Kamath, Simranjit Sekhon
The American Journal of Emergency Medicine. 2021-09-15

Abstracts/Posters

FDA authorized treatment protocol using Deltarex-G as an adjuvant/first line therapy for early-stage, triple-negative metaplastic breast cancer
Gordon E, Adnan N, Sekhon S, Kim T, Welch S, Reed RA, Hall FL, Chawla SP:, San Antonio Breast Cancer Symposium, San Antonio, Texas, 12/2021
Preliminary Efficacy from an ongoing Phase 1 dose escalation study of Seclidimistat (SP-2577) in patients with advanced sarcomas and other solid tumors
Sant P. Chawla, Victoria S. Chua-Alcala, Jasgit C. Sachdev, David S. Wages, David D. Stenehjem, Daniela Y. Santiesteban, Nadeem Q. Mirza, Simranjit Sekhon, Erlinda M. ..., CTOS, Toronto, Canada, 11/2021
A Phase 2 study of Talimogene Laherparepvec, Nivolumab, and Trabectedin (TNT) in Advanced Sarcoma
Chawla SP, Kim T, Adnan N, Sekhon S, Chua V, Moradkhani A, Bhuiyan I, Quon D, Gordon EM, CTOS, Toronto, Canada, 11/2021
) Phase 1, open label, safety study of escalating doses of Ex Vivo, expanded, Autologous Natural Killer Cells in patients with Pathologically confirmed cancer refracto...
Chawla SP, Sekhon S, Adnan N, Chua-Alcala V, Quon D, Moradkhani A, Kim T, Cha S, Gordon EM, CTOS, Toronto, Canada, 11/2021
Join now to see all